Cyclooxygenase-2 gene-1195G/A genotype is associated
with the risk of HBV-induced HCC: A case-control study in Han Chinese
people

doi:10.1007/s11684-010-0021-x

Front. Med.

2010, Vol. 4

Issue (1) : 90-95 https://doi.org/10.1007/s11684-010-0021-x

Research articles

Cyclooxygenase-2 gene-1195G/A genotype is associated with the risk of HBV-induced HCC: A case-control study in Han Chinese people

Li-Feng LIU MD, PhD¹,Qiong CHEN MD, PhD¹,Ying CHANG MD, PhD¹,Ju-Sheng LIN MD, PhD¹,Jin-Liang ZHANG MM²,

1.Institute of Liver Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2.Department of Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;

Download: PDF(190 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract This study aimed to identify functional single nucleotide polymorphisms in the cyclooxygenase-2 gene promoter and evaluate their effects on the risk of primary hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) infection. We conducted a population-based, case-control study enrolling 630 Han Chinese people in Hubei province. Subjects included primary HCC patients with HBV infection (n=210), chronic hepatitis B cases (n=210) and healthy Han Chinese (n=210). -1195G/A polymorphism was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and sequencing analysis. We found-1195A allele carriers had a higher risk of HCC with HBV infection (OR, 0.72; 95% CI, 0.548–0.946). The-1195A allele might be used as a marker in screening individuals at high risk of HCC with HBV infection.

Keywords cyclooxygenase-2 gene single nucleotide polymorphisms susceptibility primary hepatocellular carcinoma hepatitis B virus infection

Issue Date: 05 March 2010

Cite this article:

Li-Feng LIU MD,PhD,Qiong CHEN MD, et al. Cyclooxygenase-2 gene-1195G/A genotype is associated with the risk of HBV-induced HCC: A case-control study in Han Chinese people[J]. Front. Med., 2010, 4(1): 90-95.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0021-x
https://academic.hep.com.cn/fmd/EN/Y2010/V4/I1/90

	Needleman P, Turk J, Jakschik B A, Morrison A R, Lefkowith J B. Arachidonic acid metabolism. Annu RevBiochem, 1986, 55: 69―102 doi: 10.1146/annurev.bi.55.070186.000441
	Williams C S, Mann M, DuBois R N. The role of cyclooxygenases in inflammation,cancer, and development. Oncogene, 1999, 18: 7908―7916 doi: 10.1038/sj.onc.1203286
	Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasias. Ann Clin Lab Sci, 2000, 30: 3―21
	Trifan O C, Hla T. Cyclooxygenase-2modulates cellular growth and promotes tumorigenesis. Cell Mol Med, 2003, 7(3): 207―222 doi: 10.1111/j.1582-4934.2003.tb00222.x
	Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev, 2000, 19(1―2): 19―27 doi: 10.1023/A:1026575610124
	Vane J R, Bakhle Y S, Botting R M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol, 1998, 38: 97―120 doi: 10.1146/annurev.pharmtox.38.1.97
	Smith W L, Garavito R M, DeWitt D L. Prostaglandin endoperoxideH synthases (cyclooxygenases)-1 and-2. J Biol Chem, 1996, 271(52): 33157―33160 doi: 10.1074/jbc.271.52.33157
	Taketo M M. COX-2 and colon cancer. InflammRes, 1998, 47 (Suppl 2): S112―S116 doi: 10.1007/s000110050295
	Ding X Z, Tong W G, Adrian T E. Blockade of cyclooxygenase-2 inhibitsproliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res, 2000, 20(4): 2625―2631
	Li M, Wu X, Xu X C. Induction of apoptosis in colon cancercells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependentpathway. Clin Cancer Res, 2001, 7(4): 1010―1016
	Sheng H, Shao J, Washington M K, DuBois R N. Prostaglandin E2 increases growth and motility of colorectalcarcinoma cells. J Biol Chem, 2001, 276(21): 18075―18081 doi: 10.1074/jbc.M009689200
	Chen W S, Wei S J, Liu J M, Hsiao M, Kou-Lin J, Yang W K. Tumor invasiveness and liver metastasis of colon cancercells correlated with cyclooxygenase-2 (COX-2) expression and inhibitedby a COX-2-selective inhibitor, etodolac. Int J Cancer, 2001, 91(6): 894―899 doi: 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO;2-#
	Masferrer J L, Leahy K M, Koki A T, Zweifel B S, Settle S L, Woerner B M, Edwards D A, Flickinger A G, Moore R J, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 2000, 60(5): 1306―1311
	Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N. Up-regulation of cyclooxygenase 2 gene expression inhuman colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107(4): 1183―1188
	Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of cyclooxygenase-2in human lung carcinoma. Cancer Res, 1998, 58(22): 4997―5001
	Chan G, Boyle J O, Yang E K, Zhang F, Sacks P G, Shah J P, Edelstein D, Soslow R A, Koki A T, Woerner B M, Masferrer J L, Dannenberg A J. Cyclooxygenase-2 expression is up-regulated in squamouscell carcinoma of the head and neck. CancerRes, 1999, 59(5): 991―994
	Ratnasinghe D, Tangrea J, Roth M J, Dawsey S, Hu N, Anver M, Wang Q H, Taylor P R. Expression of cyclooxygenase-2in human squamous cell carcinoma of the esophagus; an immunohistochemicalsurvey. Anticancer Res, 1999, 19(1A): 171―174
	Fujita H, Koshida K, Keller E T, Takahashi Y, Yoshimito T, Namiki M, Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. Prostrate, 2002, 53(3): 232―240 doi: 10.1002/pros.10152
	Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett, 2003, 191(2): 125―135 doi: 10.1016/S0304-3835(02)00524-4
	Gupta S, Srivastava M, Ahmad N, Bostwick D G, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate, 2000, 42(1): 73―78 doi: 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G
	Chi-Man Tang T, Tung-Ping Poon R, Fan S T. The significance of cyclooxygenase-2expression in human hepatocellular carcinoma. Biomedicine & Pharmacotherapy, 2005, 59 Suppl 2: S311―S316 doi: 10.1016/S0753-3322(05)80053-8
	Lu W, Dong J, Huang Z, Guo D, Liu Y, Shi S. Comparison of four current staging systems for Chinesepatients with hepatocellular carcinoma undergoing curative resection:Okuda, CLIP, TNM and CUPI. J Gastroen Hepatol, 2008, 2(12): 1874―1878 doi: 10.1111/j.1440-1746.2008.05527.x
	Thorgeirsson S S, Grisham J W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 2002, 31(4): 339―346 doi: 10.1038/ng0802-339
	Buendia M A. Genetics of hepatocellular carcinoma. Semin Cancer Biol, 2000, 10(3): 185―200 doi: 10.1006/scbi.2000.0319
	Cox D G, Pontes C, Guino E. Polymorphisms in prostaglandin synthase2/cyclooxygen2 (PTGS2/COX-2) and risk of colorectal cancer. Br J Cancer, 2004, 91(2): 339―343
	Li M, Wu X, Xu X C. Induction of apoptosis in colon cancercells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependentpathway. Clin Cancer Res, 2001, 7(4): 1010―1016
	Sheng H, Shao J, Washington M K, DuBois R N. Prostaglandin E2 increases growth and motility of colorectalcarcinoma cells. J Biol Chem, 2001, 276(21): 8075―8081 doi: 10.1074/jbc.M009689200
	Chen W S, Wei S J, Liu J M, Hsiao M, Kou-Lin J, Yang W K. Tumor invasiveness and liver metastasis of colon cancercells correlated with cyclooxygenase-2 (COX-2) expression and inhibitedby a COX-2-selective inhibitor, etodolac. Int J Cancer, 2001, 91(6): 894―899 doi: 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO;2-#
	Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N. Up-regulation of cyclooxygenase 2 gene expression inhuman colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107(4): 1183―1188
	Hu Z, Miao X, Ma H, Wang X, Tan W, Wei Q, Lin D, Shen H. Common polymorphism in the 3’ UTRof cyclooxygenase 2 / prostaglandin synthase 2 gene and risk of lungcancerin a Chinese population. Lung Cancer, 2005, 48(1): 11―17 doi: 10.1016/j.lungcan.2004.09.004
	Chan G, Boyle J O, Yang E K, Zhang F, Sacks P G, Shah J P, Edelstein D, Soslow R A, Koki A T, Woerner B M, Masferrer J L, Dannenberg A J. Cyclooxygenase-2 expression is up-regulated in squamouscell carcinoma of the head and neck. CancerRes, 1999, 59(5): 991―994
	Ratnasinghe D, Tangrea J, Roth M J, Dawsey S, Hu N, Anver M, Wang Q H, Taylor P R. Expression of cyclooxygenase-2in human squamous cell carcinoma of the esophagus; an immunhistochemicalsurvey. Anticancer Res, 1999, 19(1A): 171―174
	Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, Qiang B, Kadlubar F F, Lin D. Identification of functionalgenetic variants in cyclooxygenase-2 and their association with riskof esophageal cancer. Gastroenterology, 2005, 129(2): 565―576
	Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, Matsuura N, Wakasa K, Nakamori S, Sakon M, Monden M. Increased expression of COX-2 in nontumor liver tissueis associated with shorter disease-free survival in patients withhepatocellular carcinoma. Clin Cancer Res, 1999, 5(12): 4005―4012
	Morinaga S, Yamamoto Y, Noguchi Y, Imada T, Rino Y, Akaike M, Sugimasa Y, Takemiya S, Kameda Y, Takanashi Y. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitisliver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol, 2002, 17(10): 1110―1116 doi: 10.1046/j.1440-1746.2002.02836.x
	Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M. Expression of cyclooxygenase-2in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 1999, 29(3): 688―696 doi: 10.1002/hep.510290355
	Casado M, Callejas N A, Rodrigo J, Zhao X, Dey S K, Bosca L, Martin-Sanz P. Contributionof cyclooxygenase 2 to liver regeneration after partial hepatectomy. FASEB J, 2001, 15(11): 2016―2018
	Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M. JTE-522, acyclooxygenase-2 inhibitor, is an effective chemopreventive agentagainst rat experimental liver fibrosis1. Gastroenterology, 2003, 125(2): 556―571 doi: 10.1016/S0016-5085(03)00904-1
	Reilly T P, Brady J N, Marchick M R, Bourdi M, George J W, Radonovich M F, Pise-Masison C A, Pohl L R. A protective role for cyclooxygenase-2 in drug-induced liver injuryin mice. Chem Res Toxicol, 2001, 14(12): 1620―1628 doi: 10.1021/tx0155505
	Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K, Eguchi K. Aspirin andNS-398 inhibit hepatocyte growth factor-induced invasiveness of humanhepatoma cells. Hepatology, 2002, 35(5): 1117―1124 doi: 10.1053/jhep.2002.32676
	Kern M A, Schubert D, Sahi D, Schoneweiss M M, Moll I, Haugg A M, Dienes H P, Breuhahn K, Schirmacher P. Proapoptotic and antiproliferativepotential of selective cyclooxygenase-2 inhibitors in human livertumor cells. Hepatology, 2002, 36(4 Pt 1): 885―894
	Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, Matsuura N, Wakasa K, Nakamori S, Sakon M, Monden M. Increased expression of COX-2 in nontumor liver tissueis associated with shorter disease-free survival in patients withhepatocellular carcinoma. Clin Cancer Res, 1999, 5(12): 4005―4012
	Nunez O, Fernandez-Martinez A, Majano P L, Apolinario A, Gomez-Gonzalo M, Benedicto I, Lopez-Cabrera M, Bosca L, Clemente G, Garcia-Monzon C, Martin-Sanz P. Increased intrahepatic cyclooxygenase-2, matrix metalloproteinase-2,and matrix metalloproteinase-9 expression is associated with progressiveliver disease in chronic hepatitis C virus infection: role of viralcore and NS5A proteins. Gut, 2004, 53(11): 1665―1672 doi: 10.1136/gut.2003.038364
	Panguluri R C, Long L O, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles R A. COX-2 gene promoter haplotypesand prostate cancer risk. Carcinogenesis, 2004, 25(6): 961―966 doi: 10.1093/carcin/bgh100
	Gao J, Ke Q, Ma H X, Wang Y, Zhou Y, Hu Z B, Zhai X J, Wang X C, Qing J W, Chen W S, Jin G F, Liu J Y, Tan Y F, Wang X R, Shen H B. Functional polymorphism inthe cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinesepopulation. J Toxicol Environ Health A, 2007, 70(11): 908―915 doi: 10.1080/15287390701289966
	Tazawa R, Xu X M, Wu K K. Characterization of the genomic structure,chromosomal location and promoter of human prostaglandin H synthase-2gene. Biochem Biophys Res Commun, 1994, 203(1): 190―199 doi: 10.1006/bbrc.1994.2167
	Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, Dong C, Shen L, Li J, Deng D, Lin D, You W. Genetic variantsin cyclooxygenase-2: Expression and risk of gastric cancer and itsprecursors in a Chinese population. Gastroenterology, 2006, 130(7): 1975―1984 doi: 10.1053/j.gastro.2006.03.021
	Vogel U, Christensen J, Wallin H, Friis S, Nex BA, Tjønneland A. Polymorphisms in COX-2, NSAIDuse and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res, 2007, 617(1,2): 138―146

[1]	Jie Pan, Zhengchao Shi, Dingsai Lin, Ningmin Yang, Fei Meng, Lang Lin, Zhencheng Jin, Qingjie Zhou, Jiansheng Wu, Jianzhong Zhang, Youming Li. Is tailored therapy based on antibiotic susceptibility effective ? A multicenter, open-label, randomized trial[J]. Front. Med., 2020, 14(1): 43-50.
[2]	Tiange Wang, Min Xu, Yufang Bi, Guang Ning. Interplay between diet and genetic susceptibility in obesity and related traits[J]. Front. Med., 2018, 12(6): 601-607.
[3]	Ying Ma,Nanxue Zhang,Shi Wu,Haihui Huang,Yanpei Cao. *Antimicrobial activity of topical agents against Propionibacterium acnes: an in vitro* study of clinical isolates from a hospital in Shanghai, China**[J]. Front. Med., 2016, 10(4): 517-521.
[4]	Jiangbo Du,Wenjie Xue,Yong Ji,Xun Zhu,Yayun Gu,Meng Zhu,Cheng Wang,Yong Gao,Juncheng Dai,Hongxia Ma,Yue Jiang,Jiaping Chen,Zhibin Hu,Guangfu Jin,Hongbing Shen. U-shaped association between telomere length and esophageal squamous cell carcinoma risk: a case-control study in Chinese population[J]. Front. Med., 2015, 9(4): 478-486.

Viewed

Full text

Abstract

Cited

Shared

Discussed